26 research outputs found
Cost-analysis of XELOX and FOLFOX4 for treatment of colorectal cancer to assist decision-making on reimbursement
<p>Abstract</p> <p>Background</p> <p>XELOX (capecitabine + oxaliplatin) and FOLFOX 4 (5-FU + folinic acid + oxaliplatin) have shown similar improvements in survival in patients with metastatic colorectal cancer (MCRC). A US cost-minimization study found that the two regimens had similar costs from a healthcare provider perspective but XELOX had lower costs than FOLFOX4 from a societal perspective, while a Japanese cost-effectiveness study found XELOX had superior cost-effectiveness. This study compared the costs of XELOX and FOLFOX4 in patients with MCRC recently treated in two oncology departments in Hong Kong.</p> <p>Methods</p> <p>Cost data were collected from the medical records of 60 consecutive patients (30 received XELOX and 30 FOLFOX4) from two hospitals. Drug costs, outpatient visits, hospital days and investigations were recorded and expressed as cost per patient from the healthcare provider perspective. Estimated travel and time costs were included in a societal perspective analysis. All costs were classed as either scheduled (associated with planned chemotherapy and follow-up) or unscheduled (unplanned visits or admissions and associated tests and medicines). Costs were based on government and hospital sources and expressed in US dollars (US2,046 for XELOX and 240 and 16,609 for XELOX and 17,836 for XELOX and $27,455 for FOLFOX4. Sensitivity analyses showed XELOX was still less costly than FOLFOX4 when using full drug regimen costs, incorporating data from a US model with costs and adverse event data from their clinical trial and with the removal of oxaliplatin from both treatment arms. Capecitabine would have to cost around four times its present price in Hong Kong for the total resource cost of treatment with XELOX to equal that of FOLFOX4.</p> <p>Conclusion</p> <p>XELOX costs less than FOLFOX4 for this patient group with MCRC from both the healthcare provider and societal perspectives.</p
Office salaries analysis National tables
SIGLEAvailable from British Library Document Supply Centre- DSC:6237.673(1991) / BLDSC - British Library Document Supply CentreGBUnited Kingdo
Survey of office salaries, hours, holidays, technology 1983
SIGLELD:8550.742(1983) / BLDSC - British Library Document Supply CentreGBUnited Kingdo
Office job evaluation
SIGLEAvailable from British Library Document Supply Centre-DSC:97/12268 / BLDSC - British Library Document Supply CentreGBUnited Kingdo
Office trend report 1991
SIGLEAvailable from British Library Document Supply Centre- DSC:6237.6975(1991) / BLDSC - British Library Document Supply CentreGBUnited Kingdo
Office automation The barriers and opportunities; report of a major new user survey
SIGLEAvailable from British Library Document Supply Centre- DSC:q91/08619(Office) / BLDSC - British Library Document Supply CentreGBUnited Kingdo
The barriers and the opportunities of information technology A management perspective
SIGLEAvailable from British Library Lending Division - LD:GPB-4529 / BLDSC - British Library Document Supply CentreGBUnited Kingdo